Alpha Tau Medical Ltd. (DRTS) Stock Analysis — Probabli.AI
AI-powered analysis for DRTS (Alpha Tau Medical Ltd.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $12.64 · Market cap: $1.1B · AI outlook: Bullish
Alpha Tau Medical Ltd. is well-positioned in the biotechnology sector, with promising technology and recent regulatory advancements boosting its outlook. While financial performance raises some concerns, the company's strategic partnerships and expanding global presence support a bullish one-year outlook. Clinical success is critical for sustaining long-term growth, and economic uncertainties…
Probabilistic 1-Year Outlook
- Bull 45% · Neutral 35% · Bear 20%
- 1-year price estimates — P10: $10 / P50: $14 / P90: $18
- Alpha Tau Medical, with recent positive regulatory approvals and successful clinical trial results, is poised for growth. Despite EPS misses and short-seller attacks, the analyst consensus remains a BUY, indicating…
5-Year Outlook
- Bull 50% · Neutral 30% · Bear 20%
- 5-year price estimates — P10: $9 / P50: $18 / P90: $30
SWOT Highlights
- Strength: Innovative cancer treatment technology (Alpha DaRT)
- Strength: Recent regulatory approvals
- Risk: Negative EPS surprises
- Risk: Financial underperformance
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
5 Wall Street analysts rate DRTS a BUY with a mean price target of $12.6.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
DRTS forecast details · DRTS sentiment details
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.